- Supported exchanges /
- F /
- 5LB.F
BIOVAXYS TECHNOLOGY CORP. (5LB F) stock market data APIs
BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune-educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. Its product pipeline includes Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and for platinum resistant ovarian cancer; MVP-S +1 Keytruda that is in IIb clinical trial to treat lung cancer, bladder cancer, liver cancer, DLBCL, and ovarian cancer subpopulations; BVX-0918, a haptenized tumor cell vaccine for ovarian cancer; and DPX SurMAGE, which is in phase I clinical stage to treat the MAGE protein family member A9 in human cancers. It also develops DPX-RSV that is in phase II clinical stage for Respiratory Syncytial Virus; DPX-Flu, which is in phase I clinical stage used to treat multiple strains of influenza; DPX-Neo, which is in phase I trial used for evaluating UConn Health's proprietary neoepitopes; DPX-E7 to evaluate changes in CD8+ T cells in peripheral blood and tumor tissue and evaluate the safety in HLA-A2positive patients; and DPX-rPA anthrax vaccine. In addition, the company operates T-Cell Antigen Discovery Program. It has agreement with AP Visionaries, Inc. to develop a proprietary DPX" formulation to address the urgent need for a therapy to treat or alleviate the potentially life-threatening risk of certain food allergies, namely those triggered by exposure to peanut/tree nuts or eggs. BioVaxys Technology Corp. is headquartered in Etobicoke, Canada.
BIOVAXYS TECHNOLOGY CORP. Financial Data Overview
| 0.037 | |
| 0.0405 | |
| - | |
| 0.0405 | |
| 0.037 | |
| 0.0046-0.0716 | |
| 11 586 K | |
| 247 M | |
| 0 | |
| -0.045 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
BIOVAXYS TECHNOLOGY CORP. Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA 0
- Earnings Per Share -0.03
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get BIOVAXYS TECHNOLOGY CORP. Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get BIOVAXYS TECHNOLOGY CORP. End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
